CITADEL ADVISORS LLC

Holdings History for BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT)

Symbol: BBOT on Nasdaq
Investment type: Equity / COMMON STOCK
Latest Disclosed Shares Owned: 2,538,142 shares
Security Ownership %: 3.2%

Shares, Excluding Options vs Price

Value, Excluding Options

Kenneth Griffin ownership in BridgeBio Oncology Therapeutics, Inc. COMMON STOCK (BBOT)

14 Nov 2025 - Kenneth Griffin has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,538,142 shares of BridgeBio Oncology Therapeutics, Inc. COMMON STOCK (BBOT). This represents 3.2% ownership of the company. This is the first filing by CITADEL ADVISORS LLC disclosing ownership of BridgeBio Oncology Therapeutics, Inc. COMMON STOCK (BBOT).

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
Kenneth Griffin	3.2%		$29,391,684	2,538,142			$11.58	13G/A	30 Sep 2025	14 Nov 2025, 16:09

Holdings date	Option	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025		0.02%	-0%	$31,679,656	2,530,324	-7,817	-0.31%	$12.52	Q4 2025
30 Sep 2025		0.02%	+0.02%	$29,391,673	2,538,141	+2,538,141	NEW	$11.58	Q3 2025

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.